8214 Federal Register / Vol. 86, No. 22 / Thursday, February 4, 2021 / Notices 

the host, and provides protective 

efficacy after a single dose. 

This technology is available for 

licensing, as a biological material, for 

commercial development in accordance 

with 35 U.S.C. 209 and 37 CFR part 404. 

Potential Commercial Applications 

• Single dose vaccine against COVID– 

19 

Competitive Advantages 

• Utilizes the established and well 

characterized VSV–EBOV vector 

• Expresses high antigen titers within 

host cells 

• Single dose protective efficacy against 

COVID–19 

• Inexpensive and replicable 

Development Stage 

• Prototype 

• In vivo/In vitro 

Inventors: Andrea Marzi (NIAID), 

Wakako Asada (NIAID). 

Licensing Contact: To license this 

technology, please contact Jeffrey 

Thruston at 301–594–5179 or 

jeffrey.thruston@nih.gov, and reference 

E–233–2017–0. 

Dated: January 19, 2021. 

Surekha Vathyam, 

Deputy Director, Technology Transfer and 

Intellectual Property Office, National Institute 

of Allergy and Infectious Diseases. 

[FR Doc. 2021–02294 Filed 2–3–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases, Special 

Emphasis Panel; NIAID New Innovators 

Awards (DP2 Clinical Trial Not Allowed). 

Date: March 2–3, 2021. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3F52, 

Rockville, MD 20892 (Virtual Meeting). 

Contact Person: Jennifer H. Meyers, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institute of Allergy and Infectious 

Diseases, National Institutes of Health, 5601 

Fishers Lane, Room 3F52, Rockville, MD 

20852, 301–761–6602, jennifer.meyers@

nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: January 26, 2021. 

Tyeshia M. Roberson, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–02276 Filed 2–3–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Library of Medicine; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable materials, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Library of 

Medicine Special Emphasis Panel; K99 and 

COI. 

Date: March 18, 2021. 

Time: 11:00 a.m. to 1:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Video Assisted Meeting. 

Contact Person: Leonid V. Tsap, Ph.D., 

Scientific Review Officer, Extramural 

Programs, National Library of Medicine, NIH, 

6705 Rockledge Drive, Suite 500, Bethesda, 

MD 20892–7968, 301–827–7077, tsapl@

mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program No. 93.879, Medical Library 

Assistance, National Institutes of Health, 

HHS) 

Dated: January 26, 2021. 

Ronald J. Livingston, Jr., 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–02279 Filed 2–3–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Biobehavioral and 

Behavioral Processes Integrated Review 

Group; Human Complex Mental Function 

Study Section. 

Date: February 24–26, 2021. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Karen Elizabeth Seymour, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, 240–762–2729, karen.seymour@

nih.gov. 

Name of Committee: Brain Disorders and 

Clinical Neuroscience Integrated Review 

Group; Acute Neural Injury and Epilepsy 

Study Section. 

Date: February 25–26, 2021. 

Time: 9:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Paula Elyse Schauwecker, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5201, 

Bethesda, MD 20892, 301–760–8207, 

schauweckerpe@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Brain Injury 

and Neurovascular Pathologies. 

Date: February 26, 2021. 

Time: 12:00 p.m. to 4:00 p.m. 


jbell on DSKJLSW7X2PROD with NOTICES